Buy or sell Guardant Health stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Guardant Health Stock
Bio-tech company focus on oncology
About Guardant Health Stock
Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.
Investors
8VC
Sila Nanotechnologies, Blend, Guardant Health, Cityblock Health, Blink Health, AnchorFree, Addepar, Illumio, Synthego, Asana
Felicis Ventures
Wish, Opendoor, Dollar Shave Club, Scopely, Plaid, SoundHound Inc., Zipline, Guardant Health, Fitbit, Hippo Insurance
Formation 8
Wish, Oscar Health, Collective Health, Blend, Virgin Hyperloop One, Guardant Health, Bolt Threads, Vicarious, NextVR, OpenGov
Khosla Ventures
Instacart, DoorDash, Stripe, Palantir Technologies, Impossible Foods, View, Opendoor, Oscar Health, Affirm, Jawbone
Lightspeed Venture Partners
Snap, OYO, AppDynamics, Epic Games, Affirm, LivingSocial, Faire, Netskope, Blend, QuantumScape
Sequoia Capital
Market Kurly, Robinhood, Airbnb, Instacart, Tokopedia, DoorDash, Stripe, UiPath, Moderna Therapeutics, Rappi
SoftBank Capital
Ola, Alibaba, SoFi, Compass, Snapdeal, Plenty, Guardant Health, BuzzFeed, Fitbit, Lemonade
Temasek Holdings
Ola, PharmEasy, Tokopedia, DoorDash, Impossible Foods, Wish, AvidXchange, Noom, Carbon, Blend
T. Rowe Price
Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Caris Life Sciences, Vroom, Ginkgo Bioworks, Deliveroo
Funding History
| April 2013 | $9.2M |
|---|---|
| April 2014 | $32.6M |
| December 2014 | $56.0M |
| December 2015 | $83.9M |
| May 2017 | $334M |
Management
Chief Executive Officer
Helmy Eltoukhy
Chief Financial Officer
Derek Bertocci
Chief Legal Officer
Michael Wiley
Chief Medical Officer
Richard Lanman
COO & President
AmirAli Talasaz
VP of Marketing
Sandra Finley
Head of Sales
Stanley Welle
VP of Bioinformatics
Darya Chudova
Vice President, Pharma Business Development
Daniel Simon
Press
Fairfield Current - Nov, 6 2018
Nasdaq - Nov, 1 2018
Nasdaq Place (press release) - Oct, 31 2018
TechCrunch - Oct, 28 2018
MarketWatch - Sep, 6 2018
GenomeWeb - Jul, 31 2018
Forbes - Jul, 19 2018
- Jul, 12 2018
PR Newswire (press release) - May, 23 2018
PR Newswire (press release) - Apr, 26 2018
Healthcare Trends - Apr, 7 2018
PR Newswire (press release) - Mar, 19 2018
PR Newswire (press release) - Mar, 13 2018
PR Newswire (press release) - Feb, 15 2018
Medgadget (blog) - Feb, 12 2018
Incredible News 24 - Jan, 22 2018
PR Newswire (press release) - Nov, 16 2017
PR Newswire (press release) - Nov, 6 2017
Medgadget (blog) - Oct, 17 2017
Healio - Oct, 5 2017
PR Newswire (press release) - Sep, 26 2017
Financial Times - Sep, 24 2017
GenomeWeb - Jun, 22 2017
GenomeWeb - Jun, 5 2017
PR Newswire (press release) - Jun, 3 2017
GenomeWeb - May, 24 2017
PR Newswire (press release) - May, 18 2017
News-Medical.net - May, 15 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Guardant Health or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
